Fritextsökning
Innehållstyper
-
Pila Pharma tar in 20 miljoner kronor – inleder ”dedikerat fetmaspår”
Malmöbolaget Pila Pharma utvecklar ett nytt, oralt läkemedel för behandling av typ 2-diabetes. Ett nytt kapitaltillskott ska användas för att initiera studier o...
-
Swedish team tests Alzheimer antibody for brain imaging
Recent breakthroughs in Alzheimer’s treatment have increased the need for precise diagnostics in the field. Researchers in Uppsala are working to develop improv...
-
Acne medication may be the solution when hair starts falling out
A treatment originally developed for acne has shown remarkable Phase III results in a completely different area: male-pattern hair loss.
-
Xbrane tar in 240 miljoner – satsar vidare på biosimilarprojekt
Biosimilarutvecklaren Xbrane Biopharma tar in 240 miljoner kronor i en riktad nyemission, som var övertecknad.
-
Abbvie i miljardaffär – tar sikte på in vivo CAR-T
Abbvie har tecknat avtal om att förvärva det kliniska biotechbolaget Capstan Therapeutics för upp till 2,1 miljarder dollar och får därmed tillgång till bland a...
-
A new scientific event in Gothenburg
Life Science Sweden is holding an event in Gothenburg for the first time.
-
New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Copenhagen (2026)
-
Budstrid om narkolepsibolag avgjord – Lundbeck drar sig ur
En uppmärksammad budstrid om det irländska biotechbolaget Avadel Pharmaceuticals har slutat med att danska Lundbeck kastar in handduken.
-
Swedish life science is growing – but capital is not keeping up
The number of employees and companies in Swedish life science is increasing and the sector is more equal than many other sectors. But investments in unlisted co...
-
Optimera flödeshanteringen med Brooks Expert Support Tool (BEST)
Brooks Instrument erbjuder ett kraftfullt verktyg för dig som arbetar med digitala massflödesmätare och massflödesregulatorer. Med den Windows-baserade mjukvara...
-
Improved processes and more
Discover the full potential and benefits.
-
Press Release
PharmaRelations appoints Niels Buch Leander as new Chief Digital Officer and Executive Vice President Denmark.
-
Canada approves leqembi as global alzheimer’s drug race heats up
Leqembi has secured approval in Canada, further consolidating its global lead among disease-modifying Alzheimer’s therapies. The antibody is now authorized in 1...
-
Webinar: Can AI replace humans in pharmacovigilance?
The webinar will explore how AI can transform pharmacovigilance by enhancing efficiency, reducing errors, and addressing challenges such as software costs, data...
-
FDA launches investigation into gene therapy following child death
The U.S. Food and Drug Administration (FDA) has initiated a safety investigation into Takeda’s Adzynma after reports that a child has died during treatment. The...
-
Anna Törner: Yes, I Am Sick, But Not Weak
”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be r...
-
Microscopy in Urinalysis: Observe Urine, Detect Abnormalities
Webinar on 18th March 2025, 10 AM - 11 AM CET.
-
In-Depth Insights into the Most Useful ZEISS Metrology Expert Tips
Free webinar June 24th, 2025, 9:00-9:45 AM and 5:00-5:45 PM.
-
Genmab drops another ADC candidate from billion‑dollar ProfoundBio deal
Danish biotech Genmab has discontinued development of its antibody‑drug conjugate (ADC) candidate GEN1160, citing low patient enrollment in an early‑stage cancer trial.
-
Astra Zeneca faces potential multimillion-dollar fines in China
Astra Zeneca could be forced to pay up up to $8 million in fines for allegedly unpaid import duties in China, as the company seeks to rebuild trust following ea...
-
Phase III win for Hansa Biopharma: “We Are Thrilled”
Swedish biotech Hansa Biopharma’s transplant drug imlifidase has met the primary efficacy endpoint in a registration-enabling Phase III study in the United States.
-
Merck KGaA acquires American company in €3.0 billion deal
Germany’s Merck is completing the acquisition of Springwork Therapeutics for 3 billion euros.
-
The vaccine has saved 94 million lives – but measles is spreading again
A disease we once believed belonged to the past is now resurging in both Europe and the United States. In the shadow of growing skepticism and declining vaccina...
-
Ny Leqembi-data antyder upp till åtta år fördröjd sjukdomsprogression
Ju tidigare lecenemab sätts in, desto större effekt kan den ha på att bromsa Alzheimers sjukdom. Det antyder nya modellerade prognoser som Bioartics partner Eisai presenterat.